Therefore, this systematic review aims to critically evaluate the existing evidence on the efficacy and safety of combined SGLT-2 inhibitor and GLP-1 receptor agonist therapy in adults with type 2 diabetes, with particular focus on its effects on glycaemic control, cardiovascular outcomes, renal function, and metabolic risk factors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.